Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Transplant Cell Ther. 2022 Feb 11;28(5):262.e1–262.e10. doi: 10.1016/j.jtct.2022.02.007

Table 4.

SURVIVAL1
EFS ± SE(%) OS ± SE(%) Relapse Cin ± SE(%)
n year 5 p-value year 5 p-value year 5 p-value
Protocol 17 17.6±9.2 0.276 17.6±9.2 0.383 76.6±12.9 0.069
Non-Protocol 5 40.0±17.9 40.0±17.9 33.3±33.3
GVHD2
Any Acute Chronic#
n No Yes No Yes No Yes
Protocol 17 8 9 9 8 7 3
Non-Protocol 5 1 4 2 3 2 2
p = 0.3602 p = 1.00 p = 0.9051
ENGRAFTMENT3
n Experienced ANC >500 Days to ANC >500 cells/μL
Mean Median SD Range p-value
Protocol 17 16 (94%) 15.9 15.5 2.3 13–20 **0.0018
Non-Protocol 5 5 (100%) 12.4 12.0 0.5 12–13
n Experienced Platelets >20 Days to Platelets >20×103 cells/μL
Mean Median SD Range p-value
Protocol 17 12 (71%) 24.0 17.5 21.9 7.0–91.0 0.6115
Non-Protocol 5 3 (60%) 22.7 25.0 6.8 15.0–28.0
1

Survival distributions compared using log-rank test. Cumulative incidence compared using Gray’s test.

2

Association of GVHD incidence with protocol status assessed with Fisher’s Exact test.

3

Continuous variables compared between groups with Wilcoxon signed-rank test.

#

of patients alive at day +100

EFS = event free survival; SE = standard error; OS = overall survival; Cin = cumulative incidence; ANC = absolute neutrophil count